sequential FMT
Biologic
sequential FMT is one of 36 biologic programs targeting Ulcerative Colitis. It is currently in development.
1
Indications
1
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
460 competitors in Ulcerative Colitis
#DrugCompanyPhaseTrials
1Tremfya
Johnson & JohnsonPhase 3
Mesalazine
FerringPhase 3
CP-690,550
PfizerPhase 3
PTM SEMA
GileadPhase 3
JNJ-42756493
Johnson & JohnsonPhase 3
RPC1063
Bristol-Myers SquibbPhase 3
Etrolizumab
RochePhase 3
Simponi
Johnson & JohnsonPreclinical
CT-P13 SC (infliximab)
CCelltrion
Phase 3
Remicade
OOrganon and Co
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ulcerative Colitis1 trial
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
Recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Phase 1/2·NCT06071312·64 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for sequential FMT. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]